Gaudium IVF and Women Health Ltd (GAUDIUMIVF) — shareholding pattern, promoter holding, financials and share price
About Gaudium IVF and Women Health Ltd (GAUDIUMIVF)
Gaudium IVF and Women Health Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as GAUDIUMIVF and on the BSE under scrip code 544709. Its ISIN is INE0P8B01020.
Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization (IVF) treatments throughout India. [1]
Listed peers in Healthcare Service Provider: Suraksha Diagnostic Ltd, One Global Service Provider Ltd, Health X Platform Ltd, 3B Blackbio DX Ltd, Chandan Healthcare Ltd, Vaidya Sane Ayurved Laboratories Ltd.
Valuation & Returns
10 Jul 2026At ₹124.6 a share on 10 Jul 2026, Gaudium IVF and Women Health Ltd (GAUDIUMIVF) was valued at a price-to-earnings ratio of 32.59x against an industry P/E of 61.73x and a price-to-book of 19.59x on a book value of ₹6.36 per share as of Mar 2025. Solomo computes return on equity of 60.11% and return on capital employed of 59.43% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2025 to Mar 2026.
- P/E
- 32.59x
- Industry P/E
- 61.73x
- P/B
- 19.59x
- EPS (TTM)
- ₹3.82
- Book value / share
- ₹6.36
- ROE
- 60.11%
- ROCE
- 59.43%
- ROA
- 31.44%
- Debt / equity
- 0.45x
- Dividend yield
- 0%
- EBITDA margin
- 36.6%
- 52-week range
- ₹69.5 – ₹133
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Gaudium IVF and Women Health Ltd (GAUDIUMIVF) reported revenue of ₹104 crore, net profit of ₹24 crore and earnings per share of ₹3.36. That compares with revenue of ₹71 crore and net profit of ₹19 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹30.35 crore and net profit ₹8.36 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 37 | 44 | 48 | 71 | 104 |
| Net profit (₹ cr) | 9 | 14 | 10 | 19 | 24 |
| EPS (₹) | 89.17 | 136.54 | 104.22 | 3.12 | 3.36 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 24.65% | 47.67% |
| Profit growth | 29.40% | 85.37% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 71.29% of Gaudium IVF and Women Health Ltd (GAUDIUMIVF) (unchanged from the previous quarter), foreign institutional investors (FII) hold 3.02% and domestic institutional investors (DII) hold 2.22%. Market capitalisation was ₹907 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Jun 2026: GDN VENTURES LLP 4.26%, MUKUL MAHAVIR AGRAWAL 3.43%, SANSHI FUND-I 1.79%, MERU INVESTMENT FUND PCC-CELL 1 1.46%, KISHAN GOPAL MOHTA 1.28%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 71.29% | - | 3.02% | 2.22% | 28.71% |
| Mar 2026 | 71.29% | - | 6.7% | 2.62% | 28.71% |